BRIEF-Additional data analyses from phase IIb trial of MIN-101 in schizophrenia under
 

BRIEF-Additional data analyses from phase IIb trial of MIN-101 in schizophrenia underscore benefit in multiple measurements of cognitive function
* Additional data analyses from phase IIb trial of MIN-101 in schizophrenia underscore benefit in multiple measurements of cognitive function Source text for Eikon: Further company coverage: http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...Gw:V_sGLiPBpWU http://feeds.feedburner.com/~ff/reut...Gw:F7zBnMyn0Lo
http://feeds.feedburner.com/~r/reute...~4/2c_X4lhILK0